ZEVRA THERAPEUTICS, INC. (ZVRA): M&A transaction — Zevra closes $150M sale of rare pediatric disease PRV, boosting cash to ~$217M

ZEVRA THERAPEUTICS, INC.

Closed sale of Rare Pediatric Disease Priority Review Voucher for $150M gross proceeds on April 1, 2025.
PRV granted by FDA in Sept 2024 following approval of MIPLYFFA for Niemann-Pick disease type C.
Unaudited cash, cash equivalents and investments at Mar 31, 2025 were $68.7M.
Pro forma cash after net proceeds of $148.3M is $217M; CFO cites support for MIPLYFFA and OLPRUVA launches and celiprolol Phase 3 trial.

item 2.01 item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ZEVRA THERAPEUTICS, INC. completed a disposition for $150.0 million (closed 2025-04-01).

Action: disposition
Consideration: $150.0 million
Closing: 2025-04-01

Exact text from the filing

the terms of an asset purchase agreement, dated February 26, 2025 (the “PRV Transfer Agreement”). Pursuant to the PRV Transfer Agreement, the Company received gross proceeds of $150.0 million from the buyer upon the closing of the Asset Sale. The foregoing description of the PRV Transfer Agreement does not purport to be complete and is qualified in its entirety by the

View on SEC.gov

Browse all m&a transactions →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-073991

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.